No connection

Search Results

GILD vs ISRG

GILD
Gilead Sciences, Inc.
NEUTRAL
Price
$132.90
Market Cap
$164.96B
Sector
Healthcare
AI Confidence
85%
ISRG
Intuitive Surgical, Inc.
NEUTRAL
Price
$465.60
Market Cap
$165.37B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GILD
19.6
ISRG
59.16
Forward P/E
GILD
13.81
ISRG
40.75
P/B Ratio
GILD
7.27
ISRG
9.28
P/S Ratio
GILD
5.6
ISRG
16.43
EV/EBITDA
GILD
12.4
ISRG
44.88

Profitability

Gross Margin
GILD
78.84%
ISRG
66.0%
Operating Margin
GILD
37.38%
ISRG
30.15%
Profit Margin
GILD
28.9%
ISRG
28.38%
ROE
GILD
40.66%
ISRG
16.69%
ROA
GILD
12.52%
ISRG
9.39%

Growth

Revenue Growth
GILD
4.7%
ISRG
18.8%
Earnings Growth
GILD
23.4%
ISRG
16.6%

Financial Health

Debt/Equity
GILD
1.13
ISRG
0.01
Current Ratio
GILD
1.55
ISRG
4.88
Quick Ratio
GILD
1.23
ISRG
3.77

Dividends

Dividend Yield
GILD
2.47%
ISRG
--
Payout Ratio
GILD
46.61%
ISRG
0.0%

AI Verdict

GILD NEUTRAL

GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.

Strengths
Exceptional profitability with 78.84% gross margins and 40.66% ROE
Highly attractive PEG ratio of 0.38 indicating undervaluation relative to growth
Strong earnings growth (YoY 23.40%) and consistent history of beating estimates
Risks
Bearish insider sentiment with selling from the CEO and CFO
Weak technical trend (0/100) indicating strong downward or stagnant momentum
Modest revenue growth (4.70%) compared to high earnings growth
ISRG NEUTRAL

ISRG exhibits a stable deterministic health profile with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet (Debt/Equity 0.01). While the company is a fundamental powerhouse with 66% gross margins and consistent earnings beats, it trades at a massive premium to its Graham Number ($94.28) and Intrinsic Value ($232.16). The disconnect between the high valuation (P/E 59.16) and the current price suggests the stock is priced for perfection, leaving little room for error despite strong 18.8% revenue growth.

Strengths
Near-zero debt profile (Debt/Equity 0.01) providing immense financial flexibility
Exceptional profitability with 66% gross margins and 28.38% profit margins
Consistent track record of earnings surprises (3/4 recent quarters beat estimates)
Risks
Extreme valuation premium (P/E 59.16, P/S 16.43) relative to historical norms
High PEG ratio (2.41) indicating the price is outstripping earnings growth
Bearish insider sentiment with 7 sell transactions and 0 buys in the last 6 months

Compare Another Pair

GILD vs ISRG: Head-to-Head Comparison

This page compares Gilead Sciences, Inc. (GILD) and Intuitive Surgical, Inc. (ISRG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile